New immune oncology drug molecules expected to result from leadXpro / InterAx partnership

Wednesday, April 18, 2018 @ 12:00 am

See the media release below on leadXpro AG and InterAx Biotech AG, joining forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

RDP Pharma and Singapore's Experimental Drug Development Centre collaborate for inflammation-driven autoimmune diseases

RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.
July 2, 2025

ten23 health joins the alliance for ready-to-use containers in sterile manufacturing

ten23 health, the human-centric and sustainable strategic CDTMO partner of choice for the pharmaceutical industry and biotech start-ups, has joined the „Alliance for RTU“, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing. The Alliance for RTU was formed in response to the market need for aseptic filling technologies and processes. It provi
June 30, 2025

Beech Biotech: USD 1.9 million to advance therapeutic approach for preeclampsia

Disease-Modifying Potential of Beech Biotech’s “Mother-Only” Antibody Programme and Platform Technology Further Underscored by Gates Foundation Grant
June 27, 2025

Sophia Genetics launches podcast series to demystify AI in healthcare

SOPHiA GENETICS has launched a new podcast series titled Decoded, hosted by CEO Dr. Jurgi Camblong. The series aims to make complex medical technologies, from AI-powered diagnostics to liquid biopsy, accessible and understandable to healthcare professionals and the wider public.
June 24, 2025

InSphero and Brenus Pharma: 3D tumor spheroids mimicking in vivo human colorectal cancer conditions

Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer.
June 19, 2025